ORENCIA DIN 02282097
Status: Marketed
Holder: BRISTOL-MYERS SQUIBB CANADA
Available to quote
Health Canada record
| Active ingredient(s) | ABATACEPT 250 MG |
|---|
| Dosage form | Powder For Solution |
|---|
| Route | Intravenous |
|---|
| Schedule | PRESCRIPTION; SCHEDULE D |
|---|
| Class | Human |
|---|
| ATC | L04AA24 ABATACEPT |
|---|
| Original market date | 08-Aug-2006 |
|---|
| Current status date | 08-Aug-2006 |
|---|
| Source | Health Canada DPD |
|---|
Establishment licence of the holder
Bristol-Myers Squibb Canada — licence 100100, currently licensed, last inspection rating C (2026-03-18).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing ABATACEPT
| DIN | Product | Company | Form | Strength | Status |
|---|
| 02402475 | ORENCIA | BRISTOL-MYERS SQUIBB CANADA | Solution | ABATACEPT 125 MG | Marketed |
| 02461919 | ORENCIA | BRISTOL-MYERS SQUIBB CANADA | Solution | ABATACEPT 125 MG | Cancelled Pre Market |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|
| 8083 | 2006-06-29 | New Drug Submission (NDS) | |
Request a quote for ORENCIA
How to read a Canadian DIN record